OneDigital Investment Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

OneDigital Investment Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-171,150	Closed	-$30K	–	870
2022 Q3	$30K	Buy	171,150 +155,000	+960%	+$158K	﹤0.01%	747
2022 Q2	$10K	Sell	16,150 -97,000	-86%	-$92.9K	﹤0.01%	706
2022 Q1	$149K	Buy	113,150 +37,000	+49%	+$60K	0.01%	716
2021 Q4	$199K	Sell	76,150 -12,000	-14%	-$36.3K	0.01%	737
2021 Q3	$274K	Buy	88,150 +35,700	+68%	+$119K	0.01%	597
2021 Q2	$195K	Buy	+52,450	New	+$175K	0.01%	689

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

OneDigital Investment Advisors's PHAS Position: Q4 2022 in Review

OneDigital Investment Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 171,150 shares — an estimated $30K sold.

OneDigital Investment Advisors first reported a position in PHAS in Q2 2021 and held it in 6 quarters. The position peaked at $274K in Q3 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

OneDigital Investment Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
OneDigital Investment Advisors sold 171,150 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $30K.
OneDigital Investment Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
OneDigital Investment Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $274K in Q3 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on OneDigital Investment Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.